LUPIN - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.1
| Stock Code | LUPIN | Market Cap | 1,04,889 Cr. | Current Price | 2,295 ₹ | High / Low | 2,378 ₹ |
| Stock P/E | 19.0 | Book Value | 596 ₹ | Dividend Yield | 0.52 % | ROCE | 21.9 % |
| ROE | 17.8 % | Face Value | 2.00 ₹ | DMA 50 | 2,232 ₹ | DMA 200 | 2,095 ₹ |
| Chg in FII Hold | 1.00 % | Chg in DII Hold | -0.98 % | PAT Qtr | 1,241 Cr. | PAT Prev Qtr | 869 Cr. |
| RSI | 55.2 | MACD | 28.5 | Volume | 11,90,656 | Avg Vol 1Wk | 8,29,049 |
| Low price | 1,774 ₹ | High price | 2,378 ₹ | PEG Ratio | 0.11 | Debt to equity | 0.04 |
| 52w Index | 86.3 % | Qtr Profit Var | 18.6 % | EPS | 120 ₹ | Industry PE | 27.6 |
📊 Chart & Trend: Lupin trades at ₹2,295, above both its 50 DMA (₹2,232) and 200 DMA (₹2,095). This indicates strong bullish momentum and sustained uptrend support.
📉 Momentum Indicators: RSI at 55.2 shows healthy momentum, not overbought. MACD at +28.5 confirms bullish strength. Bollinger Bands suggest price is near the upper band, with potential resistance around ₹2,350–₹2,370.
📈 Volume Trends: Current volume (11.9 lakh) is higher than the 1-week average (8.3 lakh), reflecting strong participation and buying interest.
🔑 Entry Zone: ₹2,230–₹2,250 (near 50 DMA support).
🚪 Exit Zone: ₹2,350–₹2,370 (near resistance and recent highs).
📌 Trend Status: The stock is trending upward with strong bullish signals, supported by moving averages and volume strength.
Positive
- Quarterly PAT surged (₹869 Cr → ₹1,241 Cr).
- EPS at ₹120 indicates robust earnings power.
- ROCE (21.9%) and ROE (17.8%) show strong efficiency.
- PEG ratio at 0.11 suggests undervaluation relative to growth.
- FII holdings increased (+1.00%), showing foreign investor confidence.
Limitation
- Stock P/E at 19.0 is below industry PE of 27.6, reflecting cautious valuation.
- DII holdings decreased (-0.98%), showing reduced domestic institutional support.
- Dividend yield at 0.52% is modest compared to peers.
Company Negative News
- DII stake reduction highlights weaker domestic institutional sentiment.
- Stock approaching upper Bollinger Band, signaling possible near-term resistance.
Company Positive News
- Sequential PAT growth highlights strong profitability momentum.
- FII stake increased, supporting long-term confidence.
Industry
- Pharma sector PE at 27.6, higher than Lupin’s valuation, suggesting relative undervaluation.
- Sector rotation favors defensive pharma stocks with strong earnings visibility.
Conclusion
⚖️ Lupin is trending upward with strong bullish signals, supported by moving averages, RSI, and MACD. Entry near ₹2,230–₹2,250 offers margin of safety, while exits around ₹2,350–₹2,370 provide profit-taking opportunities. Despite modest dividend yield and reduced DII support, strong profitability, efficiency, and undervaluation relative to peers support long-term resilience.
Would you like me to extend this into a peer benchmarking overlay with Sun Pharma, Cipla, and Dr. Reddy’s to highlight Lupin’s relative strength within the pharma sector?